文献速递真菌感染

SUBA-伊曲康唑在三级儿科医院的临床经验

Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

约60%(10/17)监测血药浓度者达到治疗水平,ABPA患儿中13/16(81%)IgE水平显示治疗反应,未因不良反应停药。

要点

  • SUBA-伊曲康唑在儿童中耐受良好,未因不良反应停药。
  • 监测血药浓度者约60%达标,部分需一次剂量调整。
  • ABPA患儿81%显示IgE水平治疗反应。

核心结论

  • SUBA-伊曲康唑在儿童中耐受良好,多数患者可快速达到治疗水平,可能是儿童真菌感染治疗或预防时优于现有口服伊曲康唑剂型的选择。

研究设计与样本

  • 推荐初始治疗剂量为5 mg/kg每日两次(最大400 mg/天),按最接近胶囊规格取整;预防剂量为2.5 mg/kg/天。

主要发现

  • 中位剂量8.5 mg/kg/天,中位疗程6周;适应证包括ABPA 16例、孢子丝菌病1例、皮肤真菌感染1例、预防1例。
  • 监测血药浓度的患者中近60%(10/17)达到治疗水平,其中7例在初始剂量下达标、3例经一次剂量调整后达标。
  • 未达治疗水平的7例患者对剂量调整建议的依从性差。
  • ABPA患儿中13/16(81%)IgE水平显示治疗反应。
  • 未因不良反应停药。

临床怎么用

  • 儿童需伊曲康唑治疗或预防真菌感染时,可考虑SUBA-伊曲康唑并监测血药浓度。
  • 对未达治疗水平者应加强剂量调整建议的依从性管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking. OBJECTIVES: To assess the safety, efficacy and attainment of therapeutic drug levels of the SUBA-itraconazole formulation in children. METHODS: A single-centre retrospective cohort study was conducted, including all patients prescribed SUBA-itraconazole from May 2018 to February 2020. The recommended initial treatment dose was 5 mg/kg twice daily (to a maximum of 400 mg/day) rounded to the nearest capsule size and 2.5 mg/kg/day for prophylaxis. RESULTS: Nineteen patients received SUBA-itraconazole and the median age was 12 years. The median dose was 8.5 mg/kg/day and the median duration was 6 weeks. Indications included ABPA (16 patients), sporotrichosis (1), cutaneous fungal infection (1) and prophylaxis (1). Of patients with serum levels measured, almost 60% (10/17) achieved a therapeutic level, 3 with one dose adjustment and 7 following the initial dose. Adherence to dose-adjustment recommendations amongst the seven patients not achieving therapeutic levels was poor. Of patients with ABPA, 13/16 (81%) demonstrated a therapeutic response in IgE level. SUBA-itraconazole was well tolerated with no cessations related to adverse effects. CONCLUSIONS: SUBA-itraconazole is well tolerated in children, with rapid attainment of therapeutic levels in the majority of patients, and may represent a superior formulation for children in whom itraconazole is indicated for treatment or prevention of fungal infection.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Abbotsford J, Foley DA, Goff Z, et al. Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital. J Antimicrob Chemother. 2021. PMID: 32929460. doi:10.1093/jac/dkaa382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。